Form 4: Design Therapeutics Director Deepa Prasad Granted 19,000 Stock Options

Design Therapeutics, Inc. Director Deepa Prasad was granted 19,000 stock options with an exercise price of $4.01, vesting over 12 months or by the next annual meeting.

Summary

• Deepa Prasad, a Director of Design Therapeutics, Inc. (DSGN), was granted 19,000 stock options.
• The stock options have an exercise price of $4.01 per share.
• The options vest in equal monthly installments over 12 months following June 10, 2025, or will be fully vested on the date of the Company's next annual meeting of stockholders, whichever comes first.
• The options are exercisable starting June 10, 2025, and expire on June 9, 2035.
• Following this transaction, Deepa Prasad beneficially owns 19,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal of continued commitment and alignment of interests between management and shareholders, incentivizing long-term performance. It is a standard compensation practice.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance and value creation.
• The vesting schedule encourages continued service and commitment from the director to the company's strategic objectives.

Risks

• The value of the granted stock options is contingent on Design Therapeutics, Inc.'s common stock price exceeding the exercise price of $4.01 per share in the future.
• If the company's stock price does not rise above the exercise price, the options may not be exercised and could expire worthless, providing no financial benefit to the holder.

Future Outlook

The grant of stock options to a director suggests a continued commitment to aligning executive incentives with long-term shareholder value creation, contingent on future stock performance.

Industry Context

This is a standard equity compensation practice within the biotechnology and pharmaceutical industries, where attracting and retaining key talent, especially directors, often involves significant equity grants to align their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• Equity grants, particularly stock options with vesting schedules, are a common form of director compensation across publicly traded companies, especially in growth-oriented sectors like biotechnology.
• The specific size of the grant (19,000 options) and the exercise price ($4.01) would typically be benchmarked against similar roles at peer companies of comparable market capitalization and stage of development, such as other clinical-stage biotech firms, to ensure competitive compensation and incentive alignment. Without specific peer compensation data, a direct quantitative comparison is not possible from this document alone.

Related Party Transactions

• The grant of stock options to Deepa Prasad, a Director of Design Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: Potential positive impact through improved director alignment and incentivized performance, but also potential future dilution if options are exercised and new shares are issued.
• Employees: No direct impact mentioned in this filing.

Next Steps

• Monitoring the vesting of these options and any subsequent exercises or sales by the director.
• Observing the company's stock performance relative to the option exercise price.

Key Dates

Recommendation

Keywords

Design Therapeutics, DSGN, Stock Option, Insider Transaction, Form 4, Deepa Prasad, Director Compensation, Equity Grant, Vesting